Humanigen - HGEN Stock Forecast, Price & News

Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called 'cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is also being studied in conjunction with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1. Ifabotuzumab has been evaluated in a Phase 1 study of glioblastoma multiforme that showed tumor specific targeting of all known tumor sites with no normal tissue uptake. HGEN005 is being explored as a treatment for a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Cantor Fitzgerald downgraded Humanigen from an "overweight" rating to a "neutral" rating in a research report on Wednesday, July 13th. HC Wainwright downgraded Humanigen from a "buy" rating to a "neutral" rating in a research report on Wednesday, July 13th. Roth Capital downgraded Humanigen from a "buy" rating to a "neutral" rating in a report on Wednesday, July 13th. Finally, Credit Suisse Group downgraded Humanigen from a "neutral" rating to an "underperform" rating in a report on Wednesday, July 13th. Two investment analysts have rated the stock with a sell rating and four have issued a hold rating to the company. Based on data from MarketBeat.com, Humanigen presently has a consensus rating of "Hold" and a consensus target price of $18.50.

Humanigen Stock Performance

Shares of NASDAQ:HGEN opened at $0.38 on Tuesday. The business's 50 day moving average price is $1.38 and its 200-day moving average price is $2.06. Humanigen has a fifty-two week low of $0.35 and a fifty-two week high of $18.22. The company has a market cap of $27.07 million, a price-to-earnings ratio of -0.16 and a beta of -1.21.

Insider Transactions at Humanigen

In other news, insider Dale Chappell acquired 545,488 shares of the company's stock in a transaction that occurred on Friday, May 20th. The shares were bought at an average price of $2.23 per share, with a total value of $1,216,438.24. Following the completion of the purchase, the insider now directly owns 8,675,081 shares in the company, valued at $19,345,430.63. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 21.70% of the company's stock.